Sugi Predict

Sugi Predict / Targets / CD22

CD22

B-cell receptor CD22 · P20273 · CD22 on Sugi Atlas →

3,448 patent compounds predicted against CD22, 1,974 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13702241 SCHEMBL13702241 0.68 17/20
SCHEMBL11940300 SCHEMBL11940300 0.59 17/20
SCHEMBL15090278 SCHEMBL15090278 0.80 16/20
SCHEMBL16362531 SCHEMBL16362531 0.80 16/20
SCHEMBL15087794 SCHEMBL15087794 0.76 16/20
SCHEMBL16362524 SCHEMBL16362524 0.73 16/20
SCHEMBL15087691 SCHEMBL15087691 0.61 16/20
SCHEMBL13415594 SCHEMBL13415594 0.57 15/20
SCHEMBL15321632 SCHEMBL15321632 0.51 15/20
SCHEMBL8457177 SCHEMBL8457177 0.48 15/20
SCHEMBL14683535 SCHEMBL14683535 0.48 15/20
SCHEMBL10699657 SCHEMBL10699657 0.50 14/20
SCHEMBL15677307 SCHEMBL15677307 0.40 14/20
SCHEMBL15087827 SCHEMBL15087827 0.64 13/20
SCHEMBL16373046 SCHEMBL16373046 0.61 13/20
SCHEMBL10708873 SCHEMBL10708873 0.54 13/20
SCHEMBL14750289 SCHEMBL14750289 0.53 13/20
SCHEMBL12919672 SCHEMBL12919672 0.52 13/20
SCHEMBL14819161 SCHEMBL14819161 0.48 13/20
SCHEMBL16373045 SCHEMBL16373045 0.75 12/20

Clinical trials — most relevant to CD22 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) PHASE4COMPLETED
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma PHASE1/PHASE2UNKNOWN
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies PHASE1/PHASE2RECRUITING
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). PHASE1/PHASE2RECRUITING
CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies PHASE1/PHASE2UNKNOWN
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1/PHASE2UNKNOWN
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia PHASE2RECRUITING
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies PHASE1/PHASE2UNKNOWN
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis PHASE2COMPLETED
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
A Study of Belimumab in the Prevention of Kidney Transplant Rejection PHASE2COMPLETED
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies PHASE1/PHASE2RECRUITING
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis PHASE2RECRUITING
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. PHASE1/PHASE2UNKNOWN
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia PHASE2RECRUITING
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma PHASE1/PHASE2WITHDRAWN
4SCAR-T Therapy Post CD19-targeted Immunotherapy PHASE1/PHASE2RECRUITING
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma PHASE1/PHASE2UNKNOWN
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma PHASE1/PHASE2UNKNOWN
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors PHASE1/PHASE2RECRUITING
CD19/22 Bi-specific CAR-T Cell Therapy PHASE1/PHASE2RECRUITING
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma PHASE1/PHASE2UNKNOWN
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies PHASE1COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1UNKNOWN
A Phase I Dose Finding Study of MB-CART2219.1 PHASE1RECRUITING
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. PHASE1UNKNOWN
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies PHASE1RECRUITING
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL EARLY_PHASE1UNKNOWN
Blinatumomab Consolidation in Real World nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CD22 binder may also engage these)

ProteinNameSimilarity
Q9N1E5 — 1.000 Q9N1E5 →
Q9N1E4 — 1.000 Q9N1E4 →
Q9N1E6 — 1.000 Q9N1E6 →
P35329 — 0.996 P35329 →
Q9N1E3 — 0.994 Q9N1E3 →
Q9EPF2 — 0.985 Q9EPF2 →
O00241 — 0.984 O00241 →
Q8R2Y2 — 0.983 Q8R2Y2 →
P04218 — 0.982 P04218 →
P06336 — 0.982 P06336 →
A8MVW5 — 0.982 A8MVW5 →
P43121 — 0.982 P43121 →
P97710 — 0.980 P97710 →
P09326 — 0.980 P09326 →
Q4VAH7 — 0.980 Q4VAH7 →
B0CLX4 — 0.980 B0CLX4 →
Q9P1W8 — 0.980 Q9P1W8 →
Q29037 — 0.980 Q29037 →
Q9D2Z1 — 0.979 Q9D2Z1 →
P18181 — 0.979 P18181 →
P06332 — 0.979 P06332 →
Q9XS78 — 0.979 Q9XS78 →
Q5TFQ8 — 0.979 Q5TFQ8 →
D3YX43 — 0.979 D3YX43 →
Q08339 — 0.979 Q08339 →
P51866 — 0.979 P51866 →
Q9D7L8 — 0.978 Q9D7L8 →
O46631 — 0.978 O46631 →
P0DUB1 — 0.978 P0DUB1 →
P97797 — 0.978 P97797 →